Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

HIV Infections 4Acquired Immunodeficiency Syndrome 4Sarcoma, Kaposi 3Lymphoma 2Head and Neck Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Pancreatic Neoplasms 1Nervous System Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Hematologic Diseases 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 17pembrolizumab 12Radiotherapy 11Nivolumab 7Cetuximab 6Paclitaxel 5fludarabine 4aldesleukin 4Radiation 4Interleukin-2 4Docetaxel 4Cyclophosphamide 4olaparib 3fludarabine phosphate 3Carboplatin 3talimogene laherparepvec 2atezolizumab 2Taxes 2Sorafenib 2Fluorouracil 2Erlotinib Hydrochloride 2Drug Therapy 2Capecitabine 2Bortezomib 2130-nm albumin-bound paclitaxel 2vandetanib 1tozuleristide 1tilsotolimod 1testosterone enanthate 1temoporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Squamous Cell × Bleomycin × Clear all
NCT01872923 2014-06-16

Dose Escalating Study for Amphinex-based PCI of Bleomycin.

PCI Biotech AS

Phase 1 Completed
3 enrolled
BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡